Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study

NCT05491616 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT05491616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05491616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
Lead sponsor
Erasmus Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 29, 2022
Completion date
October 31, 2026
Enrollment
77 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer